Physician profile
John Malone
NPI 1932415965
$3,799.47
in general payments reported to CMS, 2019-2025
38 companies · $640 in 2025
The $640 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $247 · 2021: $714 · 2022: $423 · 2023: $453 · 2024: $488 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,579.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,285.29 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $325.61 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $310.45 | 2019-2025 | Breztri |
| Pfizer INC. | $238.94 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.03 | 2019-2024 | Stiolto Respimat |
| Astellas Pharma US INC | $159.15 | 2020-2024 | Myrbetriq, Veozah |
| Sumitomo Pharma America, INC. | $128.31 | 2023-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $126.11 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $110.91 | 2021-2023 | |
| Abbott Laboratories | $110.73 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $75.49 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $60.28 | 2019-2022 | |
| Amarin Pharma, INC. | $57.61 | 2019-2021 | |
| Dexcom, INC. | $51.56 | 2023-2025 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $44.43 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valeritas, INC. | $44.00 | 2019 | |
| Boston Scientific Corporation | $32.45 | 2019-2024 | Watchman Flx |
| Insmed, INC. | $31.98 | 2025 | Arikayce |
| Fidia Pharma USA INC. | $29.37 | 2024-2025 | Hymovis, Triluron, Hyalgan |
| Amgen INC. | $26.86 | 2024-2025 | Repatha, Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $26.61 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $25.73 | 2023 | Rexulti |
| Scilex Pharmaceuticals INC. | $24.90 | 2024 | |
| Sanofi-Aventis U.S. LLC | $22.16 | 2022 | |
| Si-Bone, INC. | $21.21 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.95 | 2022 | |
| Philips North America LLC | $19.77 | 2024 | (Ae4) Secretion Management |
| Medtronic Vascular, INC. | $19.75 | 2019 | |
| Allergan, INC. | $16.52 | 2019 | |
| Esperion Therapeutics, INC. | $14.97 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.70 | 2021 | |
| Inogen, INC. | $14.23 | 2025 | |
| Verona Pharma, INC. | $14.20 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $14.05 | 2019 | |
| Nevro Corp. | $13.93 | 2023 | Senza |
| Teva Pharmaceuticals USA, INC. | $13.87 | 2020 | |
| Lucid Diagnostics INC. | $13.58 | 2023 | |
| Neurocrine Biosciences, INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.